Frequently Asked Questions (FAQs)
1. What is the purpose of this study?
The purpose of this study is to help determine if using an approved drug for the treatment of psoriasis can help slow or prevent the development of psoriatic arthritis in high-risk people. Approximately 1 in 3 people with psoriasis will go on to develop psoriatic arthritis. We currently do not know who may develop psoriatic arthritis and why. The PAMPA study will follow individuals over a two-year period who are given a medication for the treatment of psoriasis to see if this can help slow or prevent the development of psoriatic arthritis.
​
​
2. What is involved in participating?
You would schedule a screening visit with one of our medical centers to confirm that you are eligible for the study. If you are eligible and wish to participate, you would then complete several medical visits over a two-year period. You will also be asked to complete a brief survey at home every 3 months. Depending on which part of the study you decide to participate in, you may also be provided with a study drug to take at home in between visits.
​
​
3. What type of clinical trial is this?
This is a double-blind, placebo-controlled Phase 4 clinical trial. A phase 4 trial involves a drug that has already been approved and is currently on the market. The study drug in this trial is guselkumab, an approved medication for the treatment of psoriasis.
​
​
4. How do I participate?
If you are an adult with a diagnosis of psoriasis and you live in the same area as a study site - Rochester, Boston, New York City, Toronto, or St. John’s - you can reach out to our study team and someone from the study site near you will reach out to schedule a screening visit! Please contact us here.
​
​
5. Will I need to pay anything?
You will not need to pay anything to participate in this study. You also do not need health insurance to participate. The cost of tests and medical exams and the cost of the study drug are all covered by the study.
​
​
6. Where is the study being conducted?
The study is being conducted at five sites across the US and Canada. Our research sites include the NYU Grossman School of Medicine in New York City, Brigham and Women’s Center in Boston, the Women’s College Research Institute in Toronto, the University of Rochester Medical Center in Rochester, and Newlab Clinical Research in St. John’s.
​
​
7. How will I know if I’m eligible?
You may be eligible to participate if you are aged 18 or older and have received a diagnosis of psoriasis from a physician. If this sounds like you, please reach out to the study team located in your city and schedule a visit for your first screening appointment. This appointment will help us confirm if you are eligible to participate in the study.
​
​
8. Will I receive compensation?
You will receive compensation for your time. You will be provided with $65 US for each in-person study visit.
​
​
9. Can I leave the study at any time?
Yes! Participation in the study is completely voluntary and you can choose to discontinue participation at any time.
​
​
10. How long will the study last?
The study will last for a total of two years. During that time, you will need to come in for occasional medical visits and fill out a survey via email/phone every 3 months. You may also be taking a study drug at home every 2 months.
​
​
11. Can I participate if I don’t want to take any medication?
Yes! You can still participate even if you don’t want to take the study drug. You can participate in a different part of the study where you still have medical visits and we monitor your condition over the duration of the study, but you do not actually take the drug as part of the study.
​
​
​
12. Will transportation be provided to the trial sites?
At this time, transportation will not be provided but reimbursements for travel will be covered by the study.
​
​